Patents by Inventor MANDY M. LOO

MANDY M. LOO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLUCURONIDE PRODRUGS OF JANUS KINASE INHIBITORS
    Publication number: 20210032250
    Abstract: The invention relates to glucuronide prodrug compounds of Janus kinase (JAK) inhibitors having formula I: where W1, R1 and A1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.
    Type: Application
    Filed: July 13, 2020
    Publication date: February 4, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: DANIEL D. LONG, DONNA A.A. WILTON, MANDY M. LOO
  • Glucuronide prodrugs of Janus kinase inhibitors
    Patent number: 10745405
    Abstract: The invention relates to glucuronide prodrug compounds of Janus kinase (JAK) inhibitors having formula I: where W1, R1 and A1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: August 18, 2020
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Daniel D. Long, Donna A. A. Wilton, Mandy M. Loo, Ryan Hudson, Patrick J. Brassil
  • Glucuronide prodrugs of tofacitinib
    Patent number: 10472366
    Abstract: The invention relates to glucuronide prodrug compounds of the Janus kinase (JAK) inhibitor tofacitinib having formula I: where A1 and R1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: November 12, 2019
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Daniel D. Long, Donna A.A. Wilton, Mandy M. Loo
  • GLUCURONIDE PRODRUGS OF JANUS KINASE INHIBITORS
    Publication number: 20180339990
    Abstract: The invention relates to glucuronide prodrug compounds of Janus kinase (JAK) inhibitors having formula I: where W1, R1 and A1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.
    Type: Application
    Filed: May 22, 2018
    Publication date: November 29, 2018
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: DANIEL D. LONG, DONNA A.A. WILTON, MANDY M. LOO, RYAN HUDSON, PATRICK J. BRASSIL
  • GLUCURONIDE PRODRUGS OF TOFACITINIB
    Publication number: 20180258094
    Abstract: The invention relates to glucuronide prodrug compounds of the Janus kinase (JAK) inhibitor tofacitinib having formula I: where A1 and R1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.
    Type: Application
    Filed: March 7, 2018
    Publication date: September 13, 2018
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: DANIEL D. LONG, DONNA A.A. WILTON, MANDY M. LOO